Prof. Servaas Morré

Director Institute for Public Health Genomics

Focus areas

Epidemiology, diagnostics, immunogenetics and valorization of chlamydia trachomatis

Contact

Prof. S.A. Morré
Maastricht University
Institute for Public Health Genomics
PO Box 616
6200 MD Maastricht
T: (+31) (0)43 3881275
M: (+31) (0)6 30503579
E: samorretravel@yahoo.co.uk

Curriculum vitae

Prof. Servaas Morré, PhD graduated in 1994 at the VU University in Biochemistry and Molecular Biology. His PhD was on human urogenital Chlamydia trachomatis infections (VU, Amsterdam). His research is for the major part focused on the immunogenetics and public health genomics aspects of infectious diseases. He is currently working as head of the Laboratory of Immunogenetics (VUmc) and as head of the Institute for Public Health Genomics (PHG). He is working on epidemiology, diagnostics, immunogenetics and valorization of chlamydia trachomatis for more than eightteen years and he has over 150 publications. He worked on different genetic topics including plant genetics, ribosomal RNAs genetics (saccharomyces cerevisiae), Drosophila (Erasmus Fellow, Portugal) and chlamydia in the Netherlands and the USA (van Coeverden Adriani Foundation).

The aim of PHG is to systematically translate genome-based knowledge and technologies into health research (assessment), health policies (policy development) and healthcare (assurance) on the regional, national, European and international level. From the 1st of February 2012 he is professor host Pathogen Genomics in Public Health. Valorization is one of the tasks inside his professorship. Intellectual Property has been obtained in the past and linked to several spin-off companies including Microbiome Ltd, (co-founder and co-director) which won the Amsterdam Inventor Award in 2008 and the FD Gazellen Award in 2011 and 2012. Obtaining synergy between his UM and VU work and the spin-offs is a second task inside his professorship and collaborations between PhD students from both settings is ongoing. He is involved in many EU grants and the organisation of scientific meetings.

Publications (selection)

Malogajski J, Brankovic I, Verweij SP, Ambrosino E, van Agtmael MA, Brand A, Ouburg S, Morré SA.
Translational potential into health care of basic genomic and genetic findings for human immunodeficiency virus, Chlamydia trachomatis, and human papilloma virus.
Biomed Res Int. 2013;2013:892106.

Lal JA, Malogajski J, Verweij SP, de Boer P, Ambrosino E, Brand A, Ouburg S, Morré SA.
Chlamydia trachomatis infections and subfertility: opportunities to translate host pathogen genomic data into public health.
Public Health Genomics. 2013;16(1-2):50-61.

Harris SR, Clarke IN, Seth-Smith HM, Solomon AW, Cutcliffe LT, Marsh P, Skilton RJ, Holland MJ, Mabey D, Peeling RW, Lewis DA, Spratt BG, Unemo M, Persson K, Bjartling C, Brunham R, de Vries HJ, Morré SA, Speksnijder A, Bébéar CM, Clerc M, de Barbeyrac B, Parkhill J, Thomson NR.
Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing.
Nat Genet. 2012 Mar 11;44(4):413-9.

Lal JA, Schulte In den Bäumen T, Morré SA, Brand A.
Public health and valorization of genome-based technologies: a new model.
J Transl Med. 2011 Dec 5;9:e207.

Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, Elbers CC, Johnson MD, Cambi A, Huysamen C, Jacobs L, Jansen T, Verheijen K, Masthoff L, Morré SA, Vriend G, Williams DL, Perfect JR, Joosten LA, Wijmenga C, van der Meer JW, Adema GJ, Kullberg BJ, Brown GD, Netea MG.
Human dectin-1 deficiency and mucocutaneous fungal infections.
N Engl J Med. 2009 Oct 29;361(18):1760-7.